Anthony Evnin - AVEO Pharmaceuticals Independent Director
Director
Dr. Anthony B. Evnin, Ph.D., is an Independent Director of AVEO Pharmaceuticals Inc. He has served as Independent Chairman of the Board from March 2002 to 2012. He was a Partner at Venrock, a VC firm, where he focuses largely on life sciences investments and, in particular, biotechnology investments, since 1975. Dr. Evnin currently serves on the boards of Infinity Pharmaceuticals, Inc. and Pharmos Corporationrationration, both public biopharmaceutical companies, and several private biopharmaceutical companies, including Acceleron Pharma Inc., Constellation Pharmaceuticals, Inc., and Metabolex, Inc. During the last five years, Dr. Evnin served as a director of Altea Therapeutics Corporationrationration, Celladon Corporationrationration, and Syntonix Pharmaceuticals, Inc., all private biopharmaceutical companies, Kenet, Inc. a semiconductor company, and BostonPower, Inc., a lithiumion battery company, as well as the following publicly traded biopharmaceutical companies Memory Pharmaceuticals Corporationration, Sunesis, Inc., Renovis, Inc., Icagen, Inc. and Coley Pharmaceutical Group. His previous experience was as a manager of business development at Story Chemical Corporation and a research scientist at Union Carbide Corporationrationration. Dr. Evnin is a Trustee of The Rockefeller University and of The Jackson Laboratory, Trustee Emeritus of Princeton University, a Member of the Boards of Overseers and Managers of Memorial SloanKettering Cancer Center, and a Director of the New York Genome Center since 2012.
| Age | 76 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 857 400 0101 |
| Web | https://www.aveooncology.com |
AVEO Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1456) % which means that it has lost $0.1456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7253) %, meaning that it created substantial loss on money invested by shareholders. AVEO Pharmaceuticals' management efficiency ratios could be used to measure how well AVEO Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 37.96 M in liabilities with Debt to Equity (D/E) ratio of 1.26, which is about average as compared to similar companies. AVEO Pharmaceuticals has a current ratio of 3.04, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist AVEO Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, AVEO Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AVEO Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AVEO to invest in growth at high rates of return. When we think about AVEO Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Katherine Burke | Electronic Arts | N/A | |
| Richard Simonson | Electronic Arts | 59 | |
| Norman Hames | RadNet Inc | 68 | |
| Lawrence Levitt | RadNet Inc | 74 | |
| Denise Warren | Electronic Arts | 53 | |
| James Grube | GameStop Corp | 49 | |
| Heidi Ueberroth | Electronic Arts | 52 | |
| Jay Hoag | Electronic Arts | 60 | |
| Luis Ubinas | Electronic Arts | 55 | |
| Jerome Davis | GameStop Corp | 63 | |
| Talbott Roche | Electronic Arts | 51 | |
| Stephanie Shern | GameStop Corp | 69 | |
| Carrie Teffner | GameStop Corp | 53 | |
| Vivek Paul | Electronic Arts | 58 | |
| Carmen Romeo | SEI Investments | 73 | |
| Jeffrey Huber | Electronic Arts | 50 | |
| Alexander Whitelam | SEI Investments | N/A | |
| Lizabeth Dunn | GameStop Corp | 45 | |
| Gerald Szczepanski | GameStop Corp | 69 | |
| David Swartz | RadNet Inc | 73 | |
| Richard Lieb | SEI Investments | 66 | |
Management Performance
| Return On Equity | -0.73 | |||
| Return On Asset | -0.15 |
AVEO Pharmaceuticals Leadership Team
Elected by the shareholders, the AVEO Pharmaceuticals' board of directors comprises two types of representatives: AVEO Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AVEO. The board's role is to monitor AVEO Pharmaceuticals' management team and ensure that shareholders' interests are well served. AVEO Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AVEO Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mike Ferraresso, Vice President - Business Analytics and Commercial Operations | ||
| Kevin Peacock, VP Marketing | ||
| Robert Young, Independent Director | ||
| Raju Kucherlapati, Independent Director | ||
| Danielle Holland, VP Sec | ||
| David Crist, VP Sales | ||
| Michael Needle, Chief Medical Officer | ||
| Nikhil Mehta, Senior Vice President - Regulatory and Quality Assurance | ||
| Michael Ferraresso, Chief Officer | ||
| Keith Ehrlich, CFO | ||
| Henri Termeer, Independent Chairman of the Board | ||
| Jeb Ledell, Chief Officer | ||
| Kenneth Bate, Independent Director | ||
| Karuna Rubin, Senior Vice President General Counsel | ||
| Catherine DeRose, VP HR | ||
| Anthony Evnin, Independent Director | ||
| John Johnson, Independent Director | ||
| Lisa Bruneau, VP Treasurer | ||
| Emile Farhan, VP Operations | ||
| CPA CFA, Chief Officer | ||
| Monique Allaire, IR Contact Officer | ||
| Matthew Dallas, CFO | ||
| Michael Bailey, CEO and President Secretary and Director | ||
| Gregory Mayes, Independent Director |
AVEO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AVEO Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.73 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | (0.31) % | |||
| Operating Margin | (0.26) % | |||
| Current Valuation | 479.25 M | |||
| Shares Outstanding | 34.76 M | |||
| Shares Owned By Insiders | 0.19 % | |||
| Shares Owned By Institutions | 34.46 % | |||
| Number Of Shares Shorted | 816.84 K | |||
| Price To Earning | 158.21 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AVEO Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AVEO Pharmaceuticals' short interest history, or implied volatility extrapolated from AVEO Pharmaceuticals options trading.
Pair Trading with AVEO Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AVEO Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AVEO Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against AVEO Stock
| 0.55 | ARTE | Artemis Strategic | PairCorr |
The ability to find closely correlated positions to AVEO Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AVEO Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AVEO Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AVEO Pharmaceuticals to buy it.
The correlation of AVEO Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AVEO Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AVEO Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AVEO Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the AVEO Pharmaceuticals information on this page should be used as a complementary analysis to other AVEO Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in AVEO Stock
If you are still planning to invest in AVEO Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AVEO Pharmaceuticals' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |